GlassScriptPhysician profile
Aristidis Iatridis
NPI 1952309957
$10,567.75
in general payments reported to CMS, 2019-2025
38 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $712 · 2021: $1,098 · 2022: $1,762 · 2023: $1,815 · 2024: $1,736 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,742 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,741.70 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,453.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Harmony Biosciences LLC | $1,249.62 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $1,246.49 | 2019-2025 | Xywav |
| Astrazeneca Pharmaceuticals LP | $1,021.29 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $813.64 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $538.80 | 2020-2025 | |
| Axsome Therapeutics, INC. | $526.71 | 2022-2025 | Sunosi |
| Grifols USA, LLC | $480.95 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Inspire Medical Systems, INC. | $436.87 | 2019-2025 | Inspire |
| Zoll Respicardia, INC. | $369.66 | 2019-2024 | Remede System |
| Insmed, INC. | $326.44 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $245.93 | 2019-2025 | Dupixent |
| Pfizer INC. | $238.89 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.54 | 2022-2025 | Glassia, Cuvitru |
| Verona Pharma, INC. | $179.47 | 2025 | Ohtuvayre |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $155.03 | 2020-2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $118.52 | 2019-2022 | |
| Amgen INC. | $104.11 | 2022-2025 | Tezspire |
| Covis Pharma Gmbh | $97.25 | 2021-2023 | |
| United Therapeutics Corporation | $78.62 | 2019-2022 | |
| Resmed Corp | $76.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $73.87 | 2022-2023 | Belsomra |
| Lilly USA, LLC | $70.96 | 2025 | Zepbound |
| Sunovion Pharmaceuticals INC. | $68.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $66.69 | 2020-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $53.07 | 2019-2025 | |
| 3b Medical, INC. | $49.36 | 2024 | Luna |
| Viatris Specialty LLC | $44.75 | 2025 | Yupelri |
| Philips North America LLC | $37.89 | 2022-2024 | (Ak6) Vest Therapy |
| Ethicon INC. | $30.63 | 2025 | Monarch Platform |
| Baxter Healthcare | $24.11 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Csl Behring | $20.77 | 2021 | |
| Fisher & Paykel Healthcare INC | $15.90 | 2023 | Fisher & Paykel Healthcare |
| Idorsia Pharmaceuticals US INC | $15.33 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $15.07 | 2025 | Horizant |
| Phadia US INC. | $14.43 | 2023 | Immunocap |
| Eisai INC. | $13.67 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aristidis Iatridis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.